A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT)

SIMPLE SUMMARY: MEK-inhibitor monotherapy has activity in advanced NRAS(Q61R/K/L) mutant melanoma but is associated with dose-limiting cutaneous toxicity. The combination of a BRAF- with a MEK-inhibitor at their full dose (as in BRAF(V600E/K) mutant melanoma) has low cutaneous toxicity. We hypothesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, Gil, Schwarze, Julia Katharina, Tijtgat, Jens, Fasolino, Giuseppe, Everaert, Hendrik, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122428/
https://www.ncbi.nlm.nih.gov/pubmed/33921947
http://dx.doi.org/10.3390/cancers13092010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122428/
https://www.ncbi.nlm.nih.gov/pubmed/33921947
http://dx.doi.org/10.3390/cancers13092010

Ejemplares similares